This segment focuses on the development and commercialization of DefenCath, a catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs). Research and development efforts are directed towards expanding the applications of taurolidine, the active ingredient in DefenCath, to address other infectious disease challenges. The technology involves a non-antibiotic antimicrobial and antifungal approach, reducing the risk of antibiotic resistance. The segment aims to improve patient outcomes by minimizing CRBSIs, particularly in hemodialysis, oncology, and total parenteral nutrition patients. Market positioning emphasizes the unique non-antibiotic mechanism and the potential to reduce healthcare costs associated with CRBSIs. Future opportunities include expanding DefenCath's use in different clinical settings and exploring new formulations and delivery methods. Regulatory and clinical aspects involve ongoing post-market surveillance and potential label expansions based on new clinical data. CorMedix collaborates with healthcare providers and organizations to promote the adoption of DefenCath and improve infection control practices.